Loading
A phase 2 trial of SI-B001 in head and neck squamous cell carcinoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT06668961 by Sichuan Baili Pharmaceutical Co., Ltd., with 48 participants enrolled, started 2024-11-07 and due to reach its primary completion in 2026-11. Interventions recorded: SI-B001, SI-B003. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Shares SI-B001, Recurrent or metastatic head and neck squamous cell carcinoma, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
Shares SI-B001, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
Shares SI-B001, Recurrent or metastatic head and neck squamous cell carcinoma, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
Shares SI-B001, SystImmune / Sichuan Biokin.
Shares SI-B001, SystImmune / Sichuan Biokin.
Shares SI-B001, SystImmune / Sichuan Biokin.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.